270 related articles for article (PubMed ID: 26303700)
1. Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences.
Peters ME; Vaidya V; Drye LT; Devanand DP; Mintzer JE; Pollock BG; Porsteinsson AP; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG; Avramopoulos D;
J Geriatr Psychiatry Neurol; 2016 Mar; 29(2):59-64. PubMed ID: 26303700
[TBL] [Abstract][Full Text] [Related]
2. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.
Porsteinsson AP; Drye LT; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG;
JAMA; 2014 Feb; 311(7):682-91. PubMed ID: 24549548
[TBL] [Abstract][Full Text] [Related]
3. Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial.
Rosenberg PB; Drye LT; Porsteinsson AP; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Schneider LS; Shade DM; Weintraub D; Newell J; Yesavage J; Lyketsos CG;
Int Psychogeriatr; 2015 Dec; 27(12):2059-67. PubMed ID: 26305876
[TBL] [Abstract][Full Text] [Related]
4. Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial.
Ehrhardt S; Porsteinsson AP; Munro CA; Rosenberg PB; Pollock BG; Devanand DP; Mintzer J; Rajji TK; Ismail Z; Schneider LS; Baksh SN; Drye LT; Avramopoulos D; Shade DM; Lyketsos CG;
Alzheimers Dement; 2019 Nov; 15(11):1427-1436. PubMed ID: 31587995
[TBL] [Abstract][Full Text] [Related]
5. Citalopram for agitation in Alzheimer's disease: design and methods.
Drye LT; Ismail Z; Porsteinsson AP; Rosenberg PB; Weintraub D; Marano C; Pelton G; Frangakis C; Rabins PV; Munro CA; Meinert CL; Devanand DP; Yesavage J; Mintzer JE; Schneider LS; Pollock BG; Lyketsos CG;
Alzheimers Dement; 2012; 8(2):121-30. PubMed ID: 22301195
[TBL] [Abstract][Full Text] [Related]
6. Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease.
Weintraub D; Drye LT; Porsteinsson AP; Rosenberg PB; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Schneider LS; Shade DM; Yesavage J; Lyketsos CG;
Am J Geriatr Psychiatry; 2015 Nov; 23(11):1127-33. PubMed ID: 26238225
[TBL] [Abstract][Full Text] [Related]
7. Sertraline for the treatment of depression in Alzheimer disease: genetic influences.
Peters ME; Vaidya V; Drye LT; Rosenberg PB; Martin BK; Porsteinsson AP; Frangakis CE; Mintzer J; Weintraub D; Schneider LS; Rabins PV; Munro CA; Meinert CL; Lyketsos CG; Avramopoulos D;
J Geriatr Psychiatry Neurol; 2011 Dec; 24(4):222-8. PubMed ID: 22228829
[TBL] [Abstract][Full Text] [Related]
8. R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation.
Ho T; Pollock BG; Mulsant BH; Schantz O; Devanand DP; Mintzer JE; Porsteinsson AP; Schneider LS; Weintraub D; Yesavage J; Drye LT; Munro CA; Shade DM; Lyketsos C; Bies R
Br J Clin Pharmacol; 2016 Sep; 82(3):784-92. PubMed ID: 27145364
[TBL] [Abstract][Full Text] [Related]
9. Antidepressants for agitation and psychosis in dementia.
Seitz DP; Adunuri N; Gill SS; Gruneir A; Herrmann N; Rochon P
Cochrane Database Syst Rev; 2011 Feb; (2):CD008191. PubMed ID: 21328305
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial.
Schneider LS; Frangakis C; Drye LT; Devanand DP; Marano CM; Mintzer J; Mulsant BH; Munro CA; Newell JA; Pawluczyk S; Pelton G; Pollock BG; Porsteinsson AP; Rabins PV; Rein L; Rosenberg PB; Shade D; Weintraub D; Yesavage J; Lyketsos CG;
Am J Psychiatry; 2016 May; 173(5):465-72. PubMed ID: 26771737
[TBL] [Abstract][Full Text] [Related]
11. Principal components analysis of agitation outcomes in Alzheimer's disease.
Yesavage JA; Taylor JL; Friedman L; Rosenberg PB; Lazzeroni LC; Leoutsakos JS; Kinoshita LM; Perlow MJ; Munro CA; Devanand DP; Drye LT; Mintzer JE; Pollock BG; Porsteinsson AP; Schneider LS; Shade DM; Weintraub D; Lyketsos CG; Noda A;
J Psychiatr Res; 2016 Aug; 79():4-7. PubMed ID: 27115509
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Citalopram Compared to Atypical Antipsychotics on Agitation in Nursing Home Residents With Alzheimer Dementia.
Viscogliosi G; Chiriac IM; Ettorre E
J Am Med Dir Assoc; 2017 Sep; 18(9):799-802. PubMed ID: 28739492
[TBL] [Abstract][Full Text] [Related]
13. Role of citalopram in the treatment of agitation in Alzheimer's disease.
Porsteinsson AP; Keltz MA; Smith JS
Neurodegener Dis Manag; 2014; 4(5):345-9. PubMed ID: 25405648
[TBL] [Abstract][Full Text] [Related]
14. Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease.
Newell J; Yesavage JA; Taylor JL; Kraemer HC; Munro CA; Friedman L; Rosenberg PB; Madore M; Chao SZ; Devanand DP; Drye LT; Mintzer JE; Pollock BG; Porsteinsson AP; Schneider LS; Shade DM; Weintraub D; Lyketsos CG; Noda A;
J Psychiatr Res; 2016 Mar; 74():17-21. PubMed ID: 26736036
[TBL] [Abstract][Full Text] [Related]
15. Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial.
Drye LT; Spragg D; Devanand DP; Frangakis C; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Pollock BG; Porsteinsson AP; Rabins PV; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG;
PLoS One; 2014; 9(6):e98426. PubMed ID: 24914549
[TBL] [Abstract][Full Text] [Related]
16. Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease.
Tao Y; Peters ME; Drye LT; Devanand DP; Mintzer JE; Pollock BG; Porsteinsson AP; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG; Munro CA
Am J Alzheimers Dis Other Demen; 2018 Nov; 33(7):450-457. PubMed ID: 29969907
[TBL] [Abstract][Full Text] [Related]
17. When and How to Treat Agitation in Alzheimer's Disease Dementia With Citalopram and Escitalopram.
Aga VM
Am J Geriatr Psychiatry; 2019 Oct; 27(10):1099-1107. PubMed ID: 31288974
[TBL] [Abstract][Full Text] [Related]
18. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia.
Pollock BG; Mulsant BH; Rosen J; Mazumdar S; Blakesley RE; Houck PR; Huber KA
Am J Geriatr Psychiatry; 2007 Nov; 15(11):942-52. PubMed ID: 17846102
[TBL] [Abstract][Full Text] [Related]
19. Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: data from a randomized controlled trial.
Garfield LD; Dixon D; Nowotny P; Lotrich FE; Pollock BG; Kristjansson SD; Doré PM; Lenze EJ
Am J Geriatr Psychiatry; 2014 Oct; 22(10):971-9. PubMed ID: 24021217
[TBL] [Abstract][Full Text] [Related]
20. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.
Bousman CA; Stevenson JM; Ramsey LB; Sangkuhl K; Hicks JK; Strawn JR; Singh AB; Ruaño G; Mueller DJ; Tsermpini EE; Brown JT; Bell GC; Leeder JS; Gaedigk A; Scott SA; Klein TE; Caudle KE; Bishop JR
Clin Pharmacol Ther; 2023 Jul; 114(1):51-68. PubMed ID: 37032427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
